Anticancer role of Gramicidin A in myeloid leukemia
According to our findings, GA significantly reduces the leukemogenic potential of APL and CML without causing any hemolysis in RBCs, indicating its safety profile with respect to red blood cell integrity, and may eventually be a viable substitute/candidate for therapeutic intervention in APL and CML.
Authors
- Asra Noor (ORCID: https://orcid.org/0000-0002-6734-994X)
- Mudassir Khan (ORCID: https://orcid.org/0000-0002-8184-3557)
- Fazal Adnan (ORCID: https://orcid.org/0000-0002-6624-9285)
- Salik Javed Kakar (ORCID: https://orcid.org/0000-0001-9209-0880)
- Dilawar Khan (ORCID: https://orcid.org/0000-0001-5872-267X)
- Afsar Mian (ORCID: https://orcid.org/0000-0002-1995-7553)
- Syeda Maham
Institutions
- Aga Khan University (PK)
- University of Haripur (PK)
- National University of Technology (PK)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-10-09
- DOI
- https://doi.org/10.1007/s12672-025-03527-7
- Primary Topic
- Cancer therapeutics and mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00